Kura Oncology officer proposes sale of 84,929 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Kura Oncology, Inc. officer Mollie Vanessa Leoni gave notice of a proposed sale of 84,929 common shares, with an aggregate market value of approximately $812,770.53. The approximate sale date is June 18, 2026. The shares were acquired as restricted stock units and, according to the remarks, were acquired upon vesting between January 26, 2022 and January 26, 2026.
The notice lists 88,774,365 shares outstanding and March 19, 2026 as the date of plan adoption or giving of instruction for reliance on Rule 10b5-1.
Key Figures
Key Terms
Restricted Stock Units financial
Rule 10b5-1 regulatory
Aggregate Market Value financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.